To evaluate the mechanisms of resistance to MUC16-directed bispecific T-cell engagers (BITEs), we consented patients with platinum resistant ovarian cancer who had progressed on a MUC16- BITEs clinical trial to our tissue collection protocol. Here, MUC16 is linked to ovarian cancer.